ABIVAX Société Anonyme
Every calculator, already run for ABVX
Open the full toolkit →You have the numbers on ABVX. Get the argument.
A written report on which of these readings actually decide the outcome for ABIVAX Société Anonyme, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
12 analysts covering ABVXAnalyst Price Target Disagreement for ABIVAX Société Anonyme
Wall Street's bull case implies +147% from the current price; the bear case implies +94%. A 53% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for ABVX
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
ABVX — frequently asked
Is ABVX a buy right now?
Wall Street's consensus rating on ABIVAX Société Anonyme is none across 12 analysts, with a mean price target of $163.58 (+123% vs. the current $73.20). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
What is the analyst price target disagreement for ABIVAX Société Anonyme?
Analysts covering ABIVAX Société Anonyme (ABVX) range from a bear-case target of $142.00 to a bull-case high of $181.00, with a mean consensus target of $163.58 across 12 analysts. The spread of $39.00 (53% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare ABIVAX Société Anonyme against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For ABIVAX Société Anonyme
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ABVX research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on ABIVAX Société Anonyme, in minutes. 3 free reports included with every account — no credit card required.